- Jeff Clark, CEO & COO
- Robert S. White, MBA
- The Aurora Funds
- HIG Ventures
Jeff Clark, CEO & COO
Jeffrey G. Clark is uniquely qualified to lead HyperBranch in commercializing its medical devices. Jeff was formerly vice president of research and development for Closure Medical Corp., Raleigh, N.C., led the product development efforts from start-up to a $250 million cap publicly-traded company and has over 30 years of product development experience. In addition to being acknowledged for his role in leading Closure Medical's efforts to develop and manufacture medical-grade adhesives, now known as Dermabond® Topical Skin Adhesive, Jeff also designed and developed a complete line of polypropylene specialty sutures for Sharpoint, Inc.
Dermabond® adhesive was the first cyanoacrylate medical product to receive approval from the U.S. Food and Drug Administration
(FDA) for closing lacerations and incisions. Clark was named the 2001 recipient of the John W. Hyatt Award for Service to Humankind,
which was sponsored by Dow Plastics and awarded by the Society of Plastics Engineers (SPE) during its 59th Annual Technical Conference
(ANTEC) in Dallas. Clark received an M.S. degree in Chemistry from Drexel University.
Return to Top
Robert S. White, MBA
Bob assumed leadership of TYRX in January 2010. He has over 20 years of senior management experience in the medical technology industry through numerous positions of increasing responsibility with Medtronic Inc., Instromedix-LifeWatch, ALARIS Medical Systems, Eli Lilly, and General Electric. Most recently, Bob served as President of Medtronic Kyphon following the $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Bob also served as President of Physio Control, Chief Development Officer responsible for all corporate development activities, and Vice President of U.S. Sales and Global Marketing where he was responsible for commercial operations for the Medtronic Cardiac Rhythm Management business.
Bob began his career with General Electric. In 1989 he joined Eli Lilly and through successive promotional opportunities became the International Marketing Manager for IVAC based in Europe for 3 years. At ALARIS Medical Systems, a $400 million infusion therapy company, his last role was as Vice President, Corporate Development. Bob then became Founder and CEO of Liquid Borders, a healthcare software development company. At Instromedix-LifeWatch, which specializes in selling non-invasive cardiac monitoring solutions, he served as President and CEO.
Bob holds an MBA from Cornell University and a BS degree in Aerospace Engineering from the University of Missouri-Rolla.
Return to Top
Jeff Clark, MBA
Jeff Clark co-founded The Aurora Funds with Scott Albert in 1994. He works primarily with Aurora's life sciences portfolio. He pulls from his strategic planning and operational experience to help these companies create or refine business plans, build solid management teams, develop strategic partnerships and secure key customers.
Jeff currently serves on the boards of several of Aurora's life science portfolio companies, including Aldagen, Argos Therapeutics, Hyperbranch Medical Technology, Metabolon, Regado Biosciences and Xsira Pharmaceuticals assisting in the strategic direction of each.
Prior to forming Aurora, Jeff spent thirteen years working in development and external affairs for Duke University (including Duke Comprehensive Cancer Center, Duke Medical Center and the School of Engineering). Through Aurora, he hoped to close the gap between local universities and the venture capital community to facilitate the growth of life science companies.
Jeff maintains strong ties to the RTP community, serving as past Chairman of the Board of North Carolina's Council for Entrepreneurial Development, the Board of Overseers of the Duke Comprehensive Cancer Center and the Board of Directors for TROSA and the Choral Society of Durham. Jeff is also Founding Chair of NC EntrePAC and associated entities.
Jeff holds a Bachelor of Science in Mechanical Engineering from Duke University and a MBA from the Fuqua School of Business at Duke University.
Return to Top
Aaron Davidson, MBA
Mr. Davidson is a Managing Director of H.I.G. BioVentures and focuses on investment opportunities in the life sciences sector. Prior to joining H.I.G. in 2004, he was a Vice President with Ventures West with a focus on venture investing in life science companies. Mr. Davidson began his career with Lilly, where he spent a decade in various management roles in the United States and Canada including business development, strategic planning, market research and financial planning. Mr. Davidson currently serves on the boards of Alder Biopharmaceuticals, Inc., HyperBranch Medical Technology, Intact Vascular, NeurAxon Inc., Novadaq Technologies, and Tranzyme Pharma. He served on the boards of Salmedix and Gemin X Pharmaceuticals prior to their acquisitions by Cephalon in 2005 and 2011 respectively and the board of Oncogenex Pharmaceuticals prior to their public listing.
Michael Wasserman, Ph.D.
Michael focuses on investments in therapeutics and medical devices and currently serves as a director or board observer for H.I.G. portfolio companies: HyperBranch Medical Technology, Clarus Therapeutics, Tranzyme Pharma, and CardioFocus.
Prior to joining H.I.G., Michael was a Principal at Innovations Foundation, focused on the creation, financing and development of high technology companies in the life sciences, information technology and engineering sectors. At Innovations Foundation, Michael was instrumental in building multiple high growth companies derived from academic or federally sponsored research programs. Michael has also held prominent operating roles in several entrepreneurial and venture-backed life sciences efforts. Michael was a founder and Vice President, Business Development at CELLutions Biosystems (acquired by Cedarlane Laboratories), where he broadly managed business operations and was directly responsible for the successful negotiation of partnership, co-development and licensing agreements with industry leading pharmaceutical and biotechnology organizations. Michael also has extensive clinical research experience. As Director of Research at Advanced Therapeutics, Michael was involved in a series of seminal clinical studies involving biological approaches to treat rheumatoid arthritis and other autoimmune and inflammatory disorders. Earlier in his career, Michael worked directly for, or as a consultant to, several early stage life sciences businesses, and in the corporate finance, pharmaceutical and clinical research industries.